Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio Can Be Useful Markers for Distinguishing Uterine Adenomyosis and Leiomyoma
Sponsor study identifier
observational
60
0 countries
N/A
Study Start
January 2016
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
October 2016
Actual (reported)Study Completion
November 2016
Actual (reported)Both pelvic masses and preoperative diagnosis of them have still continued as an important investigation subject. It is important to discriminate the diagnoses of leiomyoma and adenomyosis before operation especially among infertile patients. Neoplasms can alter systemic or local immune response in their originating area.Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) can be readily determined by using of complete blood counter test (CBC). A high NLR has been shown in systemic inflammation, some gynecologic and gastrointestinal cancers and some cardiovascular diseases. The investigators aim to investigate using new inflammation markers, NLR and PLR, whether they are useful to discriminate between adenomyosis and leiomyoma. As far as is known, there have been no previous reports about the association among NLR, PLR, adenomyosis and leiomyoma.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
November 2016
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 2016
Date type not reportedThis date has not been verified as actual or estimated.
October 2016
Actual (reported)November 2016
Actual (reported)December 16, 2016
Actual (reported)December 20, 2016
Actual (reported)Measured serum inflammatory markers among groups by complete blood count
Those markers are neutrophil, lymphocyte and platelet count.
3 months
First group called adenomyosis was consisted of patients who were pathologically diagnosed pure adenomyosis after hysterectomy
Second group called leiomyoma was consisted of patients who were pathologically diagnosed pure leiomyoma after hysterectomy
Third group called control group was consisted of healthy patients who were pathologically diagnosed no neoplasm after hysterectomy
There were three groups in our study. First group called adenomyosis was consisted of patients who were pathologically diagnosed pure adenomyosis after hysterectomy. Second group called leiomyoma was consisted of patients who were pathologically diagnosed pure leiomyoma after hysterectomy. Third group called control group was consisted of healthy patients who were pathologically diagnosed no neoplasm after hysterectomy.
Contact the study team to confirm eligibility.
Yusuf Madendag
Kayseri Education and Research Hospital
60 participants (actual enrollment reported by the registry).
First Submitted
December 16, 2016
First Posted
December 20, 2016
Study Start
January 2016
Date type not reportedThis date has not been verified as actual or estimated.
Norwegian Adenomyosis Study II: Gene Expression Profiling of Adenomyosis
Primary Completion
October 2016
Actual (reported)Study Completion
November 2016
Actual (reported)Last Updated
December 26, 2016
Record last verified: 2016-12
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: